Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xilio Therapeutics ( (XLO) ) just unveiled an update.
On October 2, 2025, Xilio Therapeutics received approval from Nasdaq to transfer its common stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective October 6, 2025. This move follows a notice received on April 8, 2025, regarding the company’s failure to maintain the $1.00 minimum bid price required for continued listing. The transfer grants Xilio an additional 180 days, until March 30, 2026, to comply with the minimum bid price requirement, during which the stock must close at $1.00 or more for at least 10 consecutive business days.
The most recent analyst rating on (XLO) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Xilio Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company is engaged in creating tumor-selective immuno-oncology therapies aimed at improving the lives of patients with cancer.
Average Trading Volume: 569,584
Technical Sentiment Signal: Buy
Current Market Cap: $41.46M
For a thorough assessment of XLO stock, go to TipRanks’ Stock Analysis page.